Skip to content

Stock-Based Comp at other companies

TFX
TeleflexTFX
Medtronic logo
MedtronicMDT
Haemonetics logo
HaemoneticsHAE
Solventum logo
SolventumSOLV
LivaNova logo
LivaNovaLIVN
Medline, Inc.
 logo
Medline, Inc. MDLN

Other financials

Income statement

See full
Revenue$381.9M+7.5%
Gross profit$184.8M+7.4%
Operating income$44.2M+7.6%
Net income$41.0M+36.0%
EPS (diluted)$0.68+38.8%

Balance sheet

See full
Cash & equivalents$488.1M+23.4%
Total debt$821.6M+0.5%
Total equity$1.6B+13.9%
Total assets$2.7B+10.2%

Cash flow

See full
Operating cash flow$40.7M+0.3%
CapEx$16.0M-24.0%
Free cash flow$24.7M+26.5%

Valuation

See full
Market cap$4.01B-34.1%

Profitability

See full
Gross margin48.7%+0.9pp
Operating margin12.2%+0.6pp
Net margin9%+0.2pp
FCF margin14.3%+1.3pp

Returns & leverage

See full
Return on equity9.1%0.0pp
Debt / equity0.5×-0.1×
Current ratio5.1×+0.2×

Where this comes from

Reported directly by Merit Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Merit Medical Systems’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merit Medical Systems's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merit Medical Systems's stock-based comp?
Merit Medical Systems (MMSI) reported stock-based comp of $8.96M in Q1 2026.
How has Merit Medical Systems's stock-based comp changed year-over-year?
Merit Medical Systems's stock-based comp decreased by 1.3% year-over-year, from $9.08M to $8.96M.
What is the long-term trend for Merit Medical Systems's stock-based comp?
Over 4 years (2021 to 2025), Merit Medical Systems's stock-based comp has grown at a 28.2% compound annual growth rate (CAGR), from $16.09M to $43.46M.